Cellromax Sciences Co. Ltd. logo

Cellromax Sciences Co. Ltd. (471820)

Market Closed
11 Aug, 06:30
KRX SM KRX SM
4,110. 00
-25
-0.6046%
59.09B Market Cap
- P/E Ratio
- Div Yield
10,276 Volume
- Eps
4,135
Previous Close
Add Transaction
Day Range
4,030 4,230
Year Range
3,410 7,690
Want to track 471820 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

471820 closed today lower at ₩4,110, a decrease of -0.6046% from yesterday's close, completing a monthly decrease of -7.5366% or -₩335. Over the past 12 months, 471820 stock lost -37.0597%.
471820 is not paying dividends to its shareholders.
Cellromax Sciences Co. Ltd. has completed 1 stock splits, with the recent split occurring on Sep 09, 2025.
The company's stock is traded on one exchange.

471820 Chart

People also search for

Fine M-Tec Co., Ltd.
8,930
-2.5109%
Genexine Co., Ltd.
2,755
+1.2868%
TiumBio Co., Ltd.
4,950
-1.5905%
GeneOne Life Science Inc.
2,670
0%
Iljin Diamond Co. Ltd.
9,160
0%

Cellromax Sciences Co. Ltd. (471820) FAQ

What is the stock price today?

The current price is ₩4,110.00.

On which exchange is it traded?

Cellromax Sciences Co. Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 471820.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 59.09B.

Has Cellromax Sciences Co. Ltd. ever had a stock split?

Cellromax Sciences Co. Ltd. had 1 splits and the recent split was on Sep 09, 2025.

Cellromax Sciences Co. Ltd. Profile

Health Care Equipment & Supplies Industry
Healthcare Sector
- CEO
KRX SM Exchange
- ISIN
South Korea Country
- Employees
- Last Dividend
9 Sep 2025 Last Split
- IPO Date

Overview

Cellromax Sciences Co. Ltd. stands at the forefront of the pharmaceutical industry, primarily focusing on the discovery, development, and commercialization of groundbreaking medical therapies. With a keen emphasis on addressing chronic and complex health conditions, Cellromax Sciences is committed to improving patient outcomes and elevating healthcare standards across the globe. The company is recognized for its significant investments in research and development (R&D), which enable it to embark on both proprietary and collaborative projects, expanding its influence beyond individual endeavors to partnerships with leading academic institutions and industry counterparts. Its strategic position in the financial market is bolstered by a robust pipeline of innovative treatments and strategic alliances, captivating the attention of investors and stakeholders aiming to contribute to the dynamic pharmaceutical sector.

Products and Services

  • Oncology Treatments

    At the heart of Cellromax Sciences’ product lineup are its oncology treatments, designed to combat various forms of cancer through innovative therapies. These treatments leverage the latest in medical research and technology to provide new hopes for efficacy and survivorship, targeting both common and rare cancers with precision medicine approaches.

  • Neurology Solutions

    Understanding the complexity of neurological disorders, Cellromax Sciences offers a range of treatments aimed at neurology, focusing on diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. These solutions embody the company's commitment to advancing brain health and improving the quality of life for individuals affected by these challenging conditions.

  • Immunology Therapies

    Reflecting a broad perspective on human health, the company’s immunology therapies address autoimmune and inflammatory diseases, harnessing the body's immune response to treat conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These therapies are the culmination of extensive research into the immune system, aiming to restore health and balance.

Contact Information

Address: -
Phone: -